Athenex is gently turning things around for investors

Athenex Net Cash Flow or Change in Cash and Cash Equivalents is fairly stable at the moment as compared to the past year. Athenex reported Net Cash Flow or Change in Cash and Cash Equivalents of 89.11 Million in 2020. Issuance Repayment of Debt Securities is likely to rise to about 6.5 M in 2021, whereas Net Income Per Employee is likely to drop (206.8 K) in 2021. As many investors are getting excited about healthcare space, it is fair to break down Athenex. We will evaluate why we are still optimistic in anticipation of a recovery. This post is to show some fundamental factors affecting Athenex's products and services. I will also show how it may impact the investing outlook for Athenex in March.
Published over a year ago
View all stories for Athenex | View All Stories
Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.

Reviewed by Ellen Johnson

About 20.0% of Athenex shares are held by company insiders. Insiders ownership of Athenex refers to the amount of Athenex equity owned by Athenex officers, directors, relatives of the leadership team, or anyone who has access to private information before it's made available to the public. Check out our latest analysis of Athenex, including its current ownership diagnostics.
The performance of Athenex in the marketplace will significantly impact your decision to invest in its stock. Revenue growth, profitability, competitive positioning, management quality, and industry trends can influence Athenex's stock prices. When investing in Athenex, there are several factors to consider and potential outcomes to expect. As a company performs well, its stock price may increase, allowing investors to benefit from price appreciation. However, Athenex Stock can experience significant price fluctuations due to market conditions, economic factors, industry trends, or company-specific news. This is why investing in stocks such as Athenex carries risks, including the potential for capital loss. Stock prices can decline, and investors may incur losses if they sell shares at a lower price than their initial investment.

Watch out for price decline

Please consider monitoring Athenex on a daily basis if you are holding a position in it. Athenex is trading at a penny-stock level, and the possibility of delisting is much higher compared to other delisted stocks. However, just because the stock is trading under one dollar, does not mean it will be marked for deletion. Most exchanges require public instruments, such as Athenex stock to be traded above the $1 level to remain listed. If Athenex stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.

How important is Athenex's Liquidity

Athenex financial leverage refers to using borrowed capital as a funding source to finance Athenex ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Athenex financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Athenex's owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Athenex's financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the breakdown between Athenex's total debt and its cash.

Breaking it down a bit more

Athenex retains a total of 93.34 Million outstanding shares. Over half of Athenex outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to corporate investors that acquire positions in a given instrument to benefit from reduced trade commissions. Consequently, these institutions are subject to different rules and regulation than regular investors in Athenex. Please watch out for any change in the institutional holdings of Athenex as this could mean something significant has changed or about to change at the company. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.

Ownership Breakdown

Retail Investors
21.53%
Insiders
19.52%
Institutions
58.95%
Retail Investors21.53
Insiders19.52
Institutions58.95

Possible March correction of Athenex?

Athenex current kurtosis rises over 0.17. Athenex exhibits very low volatility with skewness of 0.63 and kurtosis of 0.17. However, we advise investors to further study Athenex technical indicators to make sure all market info is available and is reliable. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Athenex's stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Athenex's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Our Final Take On Athenex

While some firms within the drug manufacturers—specialty & generic industry are still a little expensive, even after the recent corrections, Athenex may offer a potential longer-term growth to investors. To conclude, as of the 28th of February 2021, our current 30 days buy-sell recommendation on the company is Strong Hold. We believe Athenex is undervalued with below average odds of financial distress for the next two years.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

Editorial Staff

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Rifka Kats do not own shares of Athenex. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com